# Sustained intraocular pressure lowering from suprachoroidal injection of a latanoprost lipid nanoparticle delivery system in the rabbit

## TL;DR

A new long-lasting eye treatment lowers pressure in rabbits, potentially improving glaucoma care.

## Contribution

A liposomal nanocarrier for latanoprost enables sustained intraocular pressure reduction via suprachoroidal injection.

## Key findings

- IOP decreased by 28% within 8 hours and reached a maximum 40% reduction at Day 5.
- Low IOP was sustained for 56 days with no adverse events observed.
- The drug returned to baseline IOP by Day 90.

## Abstract

Current treatments for glaucoma to lower intraocular pressure (IOP) are dependent on patient adherence and bioavailability after bypassing ocular barriers. Our study investigated the safety and efficacy of a liposomal nanocarrier for sustained release of latanoprost injected into the suprachoroidal space in the rabbit eye.

Dutch-Belt rabbits were injected with a single dose of 150 μL of 2 mg/mL of liposomal latanoprost formulation into the suprachoroidal space. The eyes were clinically monitored for adverse events and the IOP recorded.

IOP reduced from baseline to 8 h post liposomal latanoprost injection by 28% (5.1 ± 2.12 mmHg), reaching a maximum of 40% (7.2 ± 1.9 mmHg) at Day 5. Low IOP was sustained until Day 56 returning to baseline at Day 90. Safety assessment of the eyes showed no adverse events and good tolerability of the drug.

A single dose of liposomal latanoprost into the suprachoroidal space can lower the IOP for up to 56 days making it a promising therapeutic agent for sustained delivery drugs to the suprachoroidal space.